Guardant Health Receives Regulatory Approval for Guardant360 CDx in Japan
TOKYO, March 14, 2022 /PRNewswire/ -- The Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with advanced solid cancers. The Guardant360 CDx test was also granted approval as a...
SIFI Announces the Grant of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis
This follows the previously-granted ODD for polihexanide in Acanthamoeba Keratitis by the FDA and EMA. An estimated 15,660 patients with fungal keratitis are diagnosed annually in the US. CATANIA, Italy, March 14, 2022 /PRNewswire/ -- SIFI S.p.A. ("SIFI" or the "Company"), a leading international ophthalmic pharmaceutical company, announced today that the...
Clarivate Deals Report Highlights Emerging Trends in Biopharma Deal-Making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology related deals dominate the landscape Biotech companies in U.S. awarded largest sums of capital, followed by Mainland China and UK LONDON, March 14, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of...
Hexvix® Has Obtained CDE Approval for the Inclusion In the Clinical Real-world Evidence Pilot Study
SHANGHAI, March 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other major diseases, announced that the Hainan Provincial Medical Products Administration, in accordance with advice from the National Medical Products Administration Center for Drug Evaluation (CDE), has approved the inclusion of...
Indonesia Puts Strict Health Protocols for G20 Summit, Highlights the Importance of Pandemic Preparedness
JAKARTA, Indonesia, March 14, 2022 /PRNewswire/ -- On track to host the G20 summit in Bali on November 15-16, The Indonesia's Ministry of Health is set to implement a strict health protocol system as a precaution against COVID-19. The system will serve as a guideline for every activity during the summit. The Indonesian G20 presidency's overarching theme is "Recover Together,...
Impact Therapeutics Announces Completion of Series D1 Financing
SHANGHAI, March 14, 2022 /PRNewswire/ -- IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced the successful completion of its Series D1 financing. Institutional investors that participated in this round include new investors Dingxin Capital, CCBT, C&D EMERGING CAPITAL, Bestride, Exome Asset Management led by Sam Isaly, along...
Universiti Kebangsaan Malaysia Lecturer Finds a Potential Solution to Memory Loss
KUALA LUMPUR, Malaysia, March 14, 2022 /PRNewswire/ -- A Universiti Kebangsaan Malaysia (UKM) lecturer, Dr You Yee Xing has discovered the use of 'Cosmos Caudatus', which has been proven to be effective in preventing memory loss and increasing cognitive function among the elderly. ‘Cosmos Caudatus’ known locally as Ulam Raja or King's Salad is...
CStone announces the NMPA approval of GAVRETO (pralsetinib) for the treatment of Advanced or Metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer
GAVRETO is the first and only selective rearranged during transfection (RET) inhibitor approved in China for the treatment of RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer (TC) The labeled indications of GAVRETO have been expanded after it was approved by the NMPA in March 2021 for the treatment of locally advanced or metastatic RET...
Latest Study Shows Advantages of CanSinoBIO’s Convidecia™ as Heterologous Booster against Omicron Variant
TIANJIN, China, March 14, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that medRxiv, a preprint platform for preliminary biomedical research, published an academic paper1 on the efficacy of CanSinoBIO's Recombinant COVID-19 Vaccine ("Ad5-nCoV", trade name: Convidecia™) as a heterologous booster against the Omicron variant. The results showed that booster vaccination with either intramuscular...
Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea
SHANGHAI, March 14, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that it has entered into a license agreement with Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) to develop and commercialize NEFECON for the treatment of primary...
